Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Drug Therapy in Obesity: A Review of Current and Emerging Treatments

Open access
Williams, David M., Nawaz, Asif, Evans, Marc · 2020 · Diabetes Therapy

Abstract

Whilst the prevalence of obesity continues to increase at an alarming rate worldwide, the personal and economic burden of obesity-related complications becomes ever more important. Whilst dietary and lifestyle measures remain the fundamental focus of the patient to counter obesity, more frequently pharmacological and/or surgical interventions are required. Nevertheless, these therapies are often limited by weight loss efficacy, side effects, surgical risks and frequently obesity relapse. Currently, only five drug therapies are approved for the specific treatment of obesity. However, our understanding of the pathophysiology of obesity and of gut hormones has developed precipitously over the last 20-30 years. As a result, there has been a recent movement to create and use analogues that manipulate these gut hormones to support weight loss. In this article we review the efficacy of the currently approved drug therapies and discuss future potential drug mechanisms and early clinical trial results exploring these budding avenues. We discuss the use of glucagon-like peptide-1 (GLP-1) analogues as monotherapy and unimolecular dual or triple agonists that exploit the GLP-1 receptor and/or the gastric inhibitory peptide (GIP) receptor and/or the glucagon receptor. We also explore the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, amylin mimetics, leptin analogues, ghrelin antagonists and centrally acting agents to suppress appetite [neuropeptide Y (NPY) antagonists, melanocortin-4 receptor (MC4R) agonists and cannabinoid-1 receptor antagonists]. Whilst further evidence is required to support their clinical use, preclinical and early clinical trial results are encouraging.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-020-00816-y

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Summarises the mechanism of action for each class of pharmacotherapy used to treat obesity
Fig. 1 Summarises the mechanism of action for each class of pharmacotherapy used to treat obesityCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 96 references

Research works printed but not linked: 1

  1. Purnell JQ. Definitions, classification, and epidemiology of obesity. 2018. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. https://www.ncbi.nlm.nih.gov/books/NBK279167/. Accessed 31 Mar 2020

Cited by

See all 214

Metadata

Authors
Williams, D. M., Nawaz, A., & Evans, M.
Affiliations
University Hospital Llandough (GB)
Corresponding author
Williams, David M.
Venue
Diabetes Therapy
Published
2020-04-15
Volume
11
Issue
6
Pages
1199-1216
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W3016841284
Cited by
195
References
96
Citations by year
2026: 12 · 2025: 22 · 2024: 27 · 2023: 41 · 2022: 37 · 2021: 42 · 2020: 14
FWCI
4.43
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
anti-obesity drugs, GLP-1 receptor agonists, glucagon receptor, SGLT2 inhibitors, amylin analogues, ghrelin antagonist, melanocortin-4 receptor agonist, cannabinoid-1 receptor antagonist, gastrointestinal hormones, weight loss efficacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug Therapy in Obesity: A Review of Current and Emerging Treatments. https://app.cochat.ai/papers/10.1007/s13300-020-00816-y
The paper
Williams, D. M., Nawaz, A., & Evans, M. (2020). Drug Therapy in Obesity: A Review of Current and Emerging Treatments. Diabetes Therapy. https://doi.org/10.1007/s13300-020-00816-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.